Eli Lilly (LLY) Intangibles (2010 - 2026)

Eli Lilly has reported Intangibles for 16 years, with the latest figure at $7.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Intangibles rose 22.65% year-over-year to $7.4 billion; the trailing twelve-month figure through Mar 2026 stood at $7.4 billion (up 22.65% YoY), and the FY2025 full-year result was $6.5 billion, up 5.76% from the prior year.
• Intangibles for Q1 2026 stood at $7.4 billion, up from $6.5 billion in the prior quarter.
• The five-year high for Intangibles was $7.5 billion in Q2 2022, with the low at $5.9 billion in Q2 2025.
• Historically, Intangibles has averaged $6.8 billion across 5 years, with a median of $6.8 billion in 2023.
• Annual changes were most pronounced in 2025 — Intangibles slipped 11.09% — and 2026, when it increased 22.65%.
• Eli Lilly's Intangibles stood at $7.2 billion in 2022, then retreated by 4.16% to $6.9 billion in 2023, then decreased by 10.72% to $6.2 billion in 2024, then increased by 5.76% to $6.5 billion in 2025, then gained by 13.08% to $7.4 billion in 2026.
• The last three Intangibles figures came in at $7.4 billion (Q1 2026), $6.5 billion (Q4 2025), and $6.4 billion (Q3 2025), per Business Quant data.